Elix Inc. has entered into a drug discovery collaboration with Prism Biolab Co. Ltd. to accelerate AI-driven drug discovery for challenging protein-protein interaction targets. The partnership will combine Elix’s AI drug discovery platform with Prism’s proprietary small-molecule peptide mimetic Pepmetics technology for controlling protein-protein interactions.